Skip to main content
OpenTrials

Clinical trial condition

Triple Negative Breast Neoplasms

Explore clinical trials studying Triple Negative Breast Neoplasms. Study availability and eligibility vary by location and protocol.

819 public trials 296 recruiting studies
Refine in advanced search Browse all conditions

Triple Negative Breast Neoplasms trial results

Completed

Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)

NCT01990209

Conditions
Breast Diseases, Breast Neoplasms, Metastatic Breast Cancer, +5 more
Locations
  • Yale School of Medicine New Haven, Connecticut, United States
  • Northeast Georgia Medical Center Gainesville, Georgia, United States
  • Hope Cancer Center Terre Haute, Indiana, United States
  • Baptist Hospital East Louisville, Kentucky, United States
View Trial Details
Completed

Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors

NCT03102320

Conditions
Adenocarcinoma, Breast Diseases, Breast Neoplasms, +28 more
Locations
  • Mayo Clinic Hospital Phoenix, Arizona, United States
  • University of Southern California Los Angeles, California, United States
  • Stanford Health Care Stanford, California, United States
  • MedStar Georgetown University Hospital Washington D.C., District of Columbia, United States
View all 72 locations
View Trial Details
Completed

Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients

NCT01276899

Conditions
Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, +9 more
Locations
  • John H. Stroger, Jr. Hospital of Cook County Chicago, Illinois, United States
  • Centre Hospitalier de l'Université de Montréal -- Hotel-Dieu Montreal, Quebec, Canada
  • Centre Hospitalier de l'Université de Montréal- Notre-Dame Montreal, Quebec, Canada
  • Hôpital Royal Victoria Montreal, Quebec, Canada
View Trial Details
Completed

Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)

NCT02513472

Conditions
Breast Diseases, Breast Neoplasm, Breast Neoplasms, +5 more
Locations
  • Facility #1 Duarte, California, United States
  • Facility #1 Santa Barbara, California, United States
  • Facility #1 Denver, Colorado, United States
  • Facility #1 Miami, Florida, United States
View all 22 locations
View Trial Details
Completed

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT03071757

Conditions
Adenocarcinoma, Adenoma, Adnexal Diseases, +58 more
Locations
  • Moores Cancer Center at UC San Diego /ID# 201334 La Jolla, California, United States
  • University of California, Davis Comprehensive Cancer Center /ID# 201342 Sacramento, California, United States
  • Stanford University /ID# 206949 Stanford, California, United States
  • Yale University /ID# 207895 New Haven, Connecticut, United States
View all 27 locations
View Trial Details
Completed

A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors

NCT03000257

Conditions
Adenocarcinoma, Adenoma, Adnexal Diseases, +56 more
Locations
  • Moores Cancer Center at UC San Diego /ID# 157374 La Jolla, California, United States
  • The University of Chicago Medical Center /ID# 157375 Chicago, Illinois, United States
  • Carolina BioOncology Institute /ID# 157376 Huntersville, North Carolina, United States
  • South Texas Accelerated Research Therapeutics /ID# 157378 San Antonio, Texas, United States
View all 26 locations
View Trial Details

Related conditions